Matthias Dobbelstein

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/25067/publications.pdf

Version: 2024-02-01

56 papers	3,496 citations	185998 28 h-index	155451 55 g-index
65 all docs	65 docs citations	65 times ranked	6648 citing authors

#	Article	IF	Citations
1	p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest. Cancer Research, 2008, 68, 10094-10104.	0.4	412
2	Exploiting replicative stress to treat cancer. Nature Reviews Drug Discovery, 2015, 14, 405-423.	21.5	243
3	A polymorphic microsatellite that mediates induction of PIG3 by p53. Nature Genetics, 2002, 30, 315-320.	9.4	238
4	p21/CDKN1A Mediates Negative Regulation of Transcription by p53. Journal of Biological Chemistry, 2003, 278, 32507-32516.	1.6	205
5	Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G 2 /M Promoters. Molecular and Cellular Biology, 2005, 25, 3737-3751.	1.1	202
6	Targeting tumour-supportive cellular machineries in anticancer drug development. Nature Reviews Drug Discovery, 2014, 13, 179-196.	21.5	202
7	Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell, 2018, 34, 298-314.e7.	7.7	162
8	Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene, 1999, 18, 2101-2106.	2.6	144
9	MicroRNA-449 in cell fate determination. Cell Cycle, 2011, 10, 2874-2882.	1.3	124
10	Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. Journal of Experimental Medicine, 2012, 209, 275-289.	4.2	92
11	Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Reports, 2016, 17, 1609-1623.	2.0	88
12	Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3624-3629.	3.3	85
13	Nongenotoxic p53 Activation Protects Cells against S-Phaseâ€“Specific Chemotherapy. Cancer Research, 2006, 66, 10274-10280.	0.4	83
14	MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Molecular Cell, 2016, 61, 68-83.	4.5	82
15	Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature, 2019, 567, 545-549.	13.7	76
16	MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. Molecular Cell, 2015, 59, 243-257.	4.5	70
17	Neutralization of SARSâ€CoVâ€2 by highly potent, hyperthermostable, and mutationâ€tolerant nanobodies. EMBO Journal, 2021, 40, e107985.	3.5	69
18	Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16856-16861.	3.3	64

#	Article	IF	Citations
19	p53 Activity Results in DNA Replication Fork Processivity. Cell Reports, 2016, 17, 1845-1857.	2.9	60
20	MicroRNA-449a levels increase by several orders of magnitude during mucociliary differentiation of airway epithelia. Cell Cycle, 2010, 9, 4579-4583.	1.3	57
21	Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma. Nature Cancer, 2021, 2, 312-326.	5.7	50
22	Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11311-E11320.	3.3	44
23	Specific inhibition of Mdm2-mediated neddylation by Tip60. Cell Cycle, 2008, 7, 222-231.	1.3	39
24	BRCA1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways. Journal of Cell Biology, 2008, 182, 197-213.	2.3	33
25	Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress. Oncotarget, 2015, 6, 13072-13087.	0.8	33
26	Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity. Oncotarget, 2016, 7, 31623-31638.	0.8	33
27	A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy. Cell Cycle, 2012, 11, 2053-2054.	1.3	31
28	Usp22 deficiency impairs intestinal epithelial lineage specification in vivo. Oncotarget, 2015, 6, 37906-37918.	0.8	31
29	p63 antagonizes Wnt-induced transcription. Cell Cycle, 2010, 9, 580-587.	1.3	30
30	Mdm2 as a chromatin modifier. Journal of Molecular Cell Biology, 2017, 9, 74-80.	1.5	30
31	Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget, 2014, 5, 11778-11791.	0.8	30
32	LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition. Oncotarget, 2016, 7, 33484-33497.	0.8	30
33	The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. Journal of Clinical Investigation, 2020, 130, 5765-5781.	3.9	29
34	CDK4 inhibition diminishes p53 activation by MDM2 antagonists. Cell Death and Disease, 2018, 9, 918.	2.7	28
35	The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. Virus Research, 2021, 302, 198469.	1.1	28
36	Immunofluorescence-based screening identifies germ cell associated microRNA 302 as an antagonist to p63 expression. Cell Cycle, 2009, 8, 1426-1432.	1.3	26

#	Article	IF	Citations
37	Mdm2: Open questions. Cancer Science, 2020, 111, 2203-2211.	1.7	26
38	MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts. Molecular Cell, 2022, 82, 159-176.e12.	4.5	22
39	The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. Cell Cycle, 2014, 13, 884-889.	1.3	19
40	Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death and Differentiation, 2017, 24, 300-316.	5.0	16
41	Mdm4 supports DNA replication in a p53-independent fashion. Oncogene, 2020, 39, 4828-4843.	2.6	13
42	Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells. Oncotarget, 2015, 6, 617-632.	0.8	13
43	MDM2 binds and ubiquitinates PARP1 to enhance DNA replication fork progression. Cell Reports, 2022, 39, 110879.	2.9	13
44	Overcoming EMT-driven therapeutic resistance by BH3 mimetics. Oncoscience, 2014, 1, 706-708.	0.9	12
45	Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors. Oncotarget, 2015, 6, 32339-32352.	0.8	10
46	Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin. Cancer Letters, 2018, 428, 45-54.	3.2	9
47	Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication. IScience, 2022, 25, 104293.	1.9	9
48	HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Cancers, 2021, 13, 6163.	1.7	8
49	MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters. Biomolecules, 2022, 12, 22.	1.8	8
50	The integrated stress response induces R-loops and hinders replication fork progression. Cell Death and Disease, 2020, 11, 538.	2.7	7
51	Fortifying p53 â€“ beyond Mdm2 inhibitors. Aging, 2016, 8, 1836-1837.	1.4	5
52	Interchanging heads. Cell Cycle, 2013, 12, 11-11.	1.3	4
53	Non-hominid TP63 lacks retroviral LTRs but contains a novel conserved upstream exon. Cell Cycle, 2011, 10, 1905-1911.	1.3	3
54	G2E3 attenuating replicative stress. Aging, 2015, 7, 527-528.	1.4	3

#	Article	IF	Citations
55	Wee1 and Chk1 â€“ crosstalk between key players in replicative stress. Genes and Cancer, 2015, 6, 182-183.	0.6	2
56	EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 platinum-sensitive ovarian cancer patients.. Journal of Clinical Oncology, 2019, 37, TPS5605-TPS5605.	0.8	0